Zentek LtdTSXV:ZENView on NASDAQ
- LAST PRICE1.7900
- TODAY'S CHANGE (%)0.0300 (1.7045%)
- Bid / Lots1.6900/ 90
- Ask / Lots1.7800/ 3
- Open / Previous Close1.7500 / 1.7600
- Day Range
- 52 Week Range
- Volume152,610
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZEN |
|---|---|---|
| 09:32 ET | 14700 | 1.76 |
| 09:33 ET | 11500 | 1.73 |
| 09:35 ET | 200 | 1.73 |
| 09:37 ET | 3400 | 1.73 |
| 09:46 ET | 200 | 1.71 |
| 09:48 ET | 4000 | 1.71 |
| 09:55 ET | 200 | 1.69 |
| 09:57 ET | 600 | 1.69 |
| 10:18 ET | 1500 | 1.7 |
| 10:27 ET | 500 | 1.72 |
| 10:31 ET | 2200 | 1.72 |
| 10:36 ET | 25800 | 1.78 |
| 10:38 ET | 11300 | 1.8 |
| 10:40 ET | 7300 | 1.82 |
| 10:42 ET | 3700 | 1.81 |
| 10:44 ET | 1500 | 1.82 |
| 10:45 ET | 800 | 1.82 |
| 10:47 ET | 600 | 1.82 |
| 10:51 ET | 2000 | 1.79 |
| 10:54 ET | 100 | 1.81 |
| 10:56 ET | 3200 | 1.82 |
| 11:00 ET | 500 | 1.82 |
| 11:03 ET | 1100 | 1.82 |
| 11:05 ET | 3900 | 1.82 |
| 11:12 ET | 100 | 1.81 |
| 11:18 ET | 500 | 1.82 |
| 11:20 ET | 1800 | 1.82 |
| 11:21 ET | 2200 | 1.81 |
| 11:23 ET | 800 | 1.76 |
| 11:30 ET | 1600 | 1.77 |
| 11:39 ET | 500 | 1.79 |
| 11:41 ET | 400 | 1.77 |
| 12:03 ET | 200 | 1.77 |
| 12:06 ET | 1400 | 1.74 |
| 12:12 ET | 900 | 1.8 |
| 01:15 ET | 1600 | 1.78 |
| 01:22 ET | 1200 | 1.75 |
| 01:36 ET | 700 | 1.73 |
| 01:44 ET | 2600 | 1.79 |
| 02:30 ET | 7100 | 1.78 |
| 02:41 ET | 100 | 1.79 |
| 02:57 ET | 200 | 1.8 |
| 02:59 ET | 300 | 1.8 |
| 03:01 ET | 4700 | 1.81 |
| 03:03 ET | 200 | 1.81 |
| 03:06 ET | 100 | 1.8 |
| 03:08 ET | 6200 | 1.81 |
| 03:12 ET | 600 | 1.81 |
| 03:21 ET | 100 | 1.8 |
| 03:24 ET | 300 | 1.81 |
| 03:39 ET | 500 | 1.78 |
| 03:42 ET | 4500 | 1.8 |
| 03:44 ET | 200 | 1.79 |
| 03:48 ET | 200 | 1.79 |
| 03:51 ET | 5400 | 1.8 |
| 03:53 ET | 2000 | 1.79 |
| 03:57 ET | 1800 | 1.79 |
Nov 6, 2024
Zentek and Triera Biosciences Ltd. Receive $1.1 Million Government of Canada Contract to Test Multivalent Aptamer Technology, from 7:16AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:16AM ET on Wednesday Nov 06, 2024 by Dow Jones
Oct 31, 2024
Zentek Provides Regulatory Update for ZenGUARD(TM) Enhanced Air Filters, from 7:16AM ET on Thursday Oct 31, 2024 by Dow Jones
7:16AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentek Ltd | 183.2M | -16.2x | --- |
Cardiol Therapeutics Inc | 202.9M | -5.7x | --- |
Eupraxia Pharmaceuticals Inc | 156.0M | -3.1x | --- |
NervGen Pharma Corp | 146.9M | -6.1x | --- |
Medicenna Therapeutics Corp | 110.8M | -4.3x | --- |
Oncolytics Biotech Inc | 106.3M | -3.8x | --- |
Company Information
Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company’s developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis.
Contact Information
- Headquarters
- 24 Corporate CtGUELPH, ON, Canada N1G 5G5
- Phone
- 705-618-0900
- Fax
- 705-618-0900
Executives
- Non-Executive Chairman of the Board
- Eric Wallman
- Chief Executive Officer, Director
- Gregory Fenton
- Chief Financial Officer
- Wendy Ford
- Vice President - Science and Research
- Colin Van Der Kuur
- Vice President - Strategy, Business Development and Investor Relations
- Ryan Shacklock
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $183.2M |
|---|---|
Revenue (TTM) | $35.3K |
Shares Outstanding | 104.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.11 |
Book Value | $0.20 |
P/E Ratio | -16.2x |
Price/Sales (TTM) | 5,187.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -32,839.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
